|
March 14, 2006 Categories: Uncategorized Posted by admin
X-Cell Medical, Inc. announced 8 March that the Company has initiated enrollment in its multinational clinical trial to study the safety and effectiveness of the ETHOS (EsTradiol eluting stents in Humans for restenOSis) II Coronary Stent System.
ETHOS II drug eluting stents (DES) are coated with a second generation formulation of 17(beta)-estradiol, an approved drug used in hormone replacement therapy and other indications. The ETHOS II trial is complimentary to the Company’s ongoing ETHOS I trial, with full 6-month follow-up data to be reported in 2H 2006.
Full News
|
|
